Abbott’s molecular diagnostics business has entered into an agreement with Genentech, Inc., F. Hoffmann-La Roche and OSI Pharmaceuticals, Inc. to develop a gene test to assess the clinical benefit of Tarceva, an oral tablet indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.      Under the agreement, Abbott will develop a test to detect extra copies of the epidermal growt...